OSTEOPOROSIS TREATMENT WITH BIOSIMILARS IN MALAYSIA AND THAILAND: A BUDGET IMPACT ANALYSIS
Author(s)
Linda Siachalinga, MSc1, Martin J. Downes, PhD2, Arun Jones, MSc3, Igor Solev, PhD4, Kenneth KC Lee, BSc, MS, RPh, PhD5, Thanut Valleenukul, PhD6, Kyoo Kim, MSc7, Hansoo Kim, BSc, MSc, PhD8.
1Griffith University, Southport, Australia, 2School of Medicine and Dentistry, Griffith University, Nathan, Australia, 3Griffith University, Gold Coast, Australia, 4AbbottPharmaceuticals, Allschwil, Switzerland, 5Monash University Malaysia, Subang Jaya, Malaysia, 6Bhumibol Adulyadej Hospital, Department of Orthopedic Surgery, Thailand, 7Abbott Products Operations AG, Allschwil, Switzerland, 8Bond University, Robina, Australia.
1Griffith University, Southport, Australia, 2School of Medicine and Dentistry, Griffith University, Nathan, Australia, 3Griffith University, Gold Coast, Australia, 4AbbottPharmaceuticals, Allschwil, Switzerland, 5Monash University Malaysia, Subang Jaya, Malaysia, 6Bhumibol Adulyadej Hospital, Department of Orthopedic Surgery, Thailand, 7Abbott Products Operations AG, Allschwil, Switzerland, 8Bond University, Robina, Australia.
OBJECTIVES: Biologic treatments demonstrate long-term clinical benefits for patients with osteoporosis, but their cost is prohibitive, and access can be limited, particularly in low-income countries. This analysis determined the cost impact of introducing biosimilar denosumab for the treatment of osteoporosis in Malaysia and Thailand.
METHODS: A budget impact model was developed to compare the cost of treating female patients aged ≥50 years with osteoporosis with biosimilar versus reference denosumab (60 mg/mL every 6 months) from a healthcare payer perspective in Malaysia and Thailand over 5-years. Model inputs included previously published, country-specific prevalence, incidence, mortality, and treatment data, supplemented by expert clinical advice where evidence was limited. Drug acquisition cost was assumed to cost 25% less than the reference product. Further assumptions included no change in osteoporosis incidence and mortality over the time horizon and consistent condition-related costs across both scenarios.
RESULTS: Over 5 years, treatment with the reference denosumab was estimated to cost MYR ~864 million (USD ~217 million) in Malaysia and THB ~179.5 billion (USD ~ 5.2 billion) in Thailand. Biosimilar denosumab was estimated to cost MYR ~648 million (USD ~162 million) and THB ~134.6 billion (USD ~3.9 billion), resulting in potential savings of MYR ~216 million (USD ~54 million) and THB 44.8 billion (USD ~1.3 billion), respectively.
CONCLUSIONS: The introduction of biosimilar denosumab in Malaysia and Thailand could yield significant cost savings and enhance access to biologic therapies for postmenopausal women with osteoporosis. The inclusion of biosimilar denosumab in national osteoporosis management programs could lead to increased uptake, but it is not explored in this analysis and requires further consideration.
METHODS: A budget impact model was developed to compare the cost of treating female patients aged ≥50 years with osteoporosis with biosimilar versus reference denosumab (60 mg/mL every 6 months) from a healthcare payer perspective in Malaysia and Thailand over 5-years. Model inputs included previously published, country-specific prevalence, incidence, mortality, and treatment data, supplemented by expert clinical advice where evidence was limited. Drug acquisition cost was assumed to cost 25% less than the reference product. Further assumptions included no change in osteoporosis incidence and mortality over the time horizon and consistent condition-related costs across both scenarios.
RESULTS: Over 5 years, treatment with the reference denosumab was estimated to cost MYR ~864 million (USD ~217 million) in Malaysia and THB ~179.5 billion (USD ~ 5.2 billion) in Thailand. Biosimilar denosumab was estimated to cost MYR ~648 million (USD ~162 million) and THB ~134.6 billion (USD ~3.9 billion), resulting in potential savings of MYR ~216 million (USD ~54 million) and THB 44.8 billion (USD ~1.3 billion), respectively.
CONCLUSIONS: The introduction of biosimilar denosumab in Malaysia and Thailand could yield significant cost savings and enhance access to biologic therapies for postmenopausal women with osteoporosis. The inclusion of biosimilar denosumab in national osteoporosis management programs could lead to increased uptake, but it is not explored in this analysis and requires further consideration.
Conference/Value in Health Info
2026-09, ISPOR Asia Pacific 2026, Bangkok, Thailand
Value in Health, Volume 55, Issue S1
Code
EE50
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
SDC: Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)